Brind.

Goldman Sachs reduced its price target on MRK stock, while the company anticipates supportive data from a Hyperion trial.

1 report, 1 independent Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Goldman Sachs reduced its price target on MRK stock, while the company anticipates supportive data from a Hyperion trial.

Who's involved

What this event is mainly about
MRKGoldman Sachs

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyGoldman Sachs Reduced the PT on Merck & Co., Inc. (MRK), Kept a Buy Rating Merck & Co., Inc. (NYSE:MRK) is one of the Best Stocks to Invest in for High Returns. On July 30, Goldman Sachs analyst Asad